Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 2:00 PM EDT
Company Participants
Ryan Crowe – Senior Vice President of Investor Relations & Strategic Analysis
Christopher Fenimore – Executive VP of Finance & CFO
L. Sirulnik – Senior VP and Clinical Development Unit Head of Hematology
Conference Call Participants
Salveen Richter – Goldman Sachs Group, Inc., Research Division
Presentation
Salveen Richter
Goldman Sachs Group, Inc., Research Division
Good afternoon, everyone. Thank you so much for joining us. Really pleased to have with us the Regeneron team. Next to me is Chris Fenimore, CFO; Andres Sirulnik, SVP, Clinical Development Unit Head of Hematology and Ryan Crowe, IR and strategic analysis. And Ryan, let me turn it over to you.
Ryan Crowe
Senior Vice President of Investor Relations & Strategic Analysis
Just to get this out of the way. And Salveen, thank you very much for having us. Great to be back in Miami again to see a lot of familiar faces and excited to have this chat. But first, let me get through this forward-looking statement disclaimer.
I’d like to remind you that remarks made today may include forward-looking statements about Regeneron, and each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in such statements. A description of material risks and uncertainties can be found in Regeneron’s SEC filings that are on our website. And with that, Salveen, let’s jump in.
Question-and-Answer Session
Salveen Richter
Goldman Sachs Group, Inc., Research Division
Great. Chris, to start here, Regeneron has been challenged recently on both the earnings front, driven by headwinds facing the EYLEA franchise. And on the pipeline, most recently for fianlimab Phase III failure. In that context, how do you see the company positioned from here for second half of the
You must be logged in to post a comment Login